Cabozantinib and apixaban: an hitherto unreported interaction

The use of direct oral anticoagulant in cancer patients is an emerging issue, which seems to be an alternative to low molecular weight heparin. Every year several new drugs are approved as anticancer treatment with possible drug-drug interaction with other drugs such as oral anticoagulant. We descri...

Descripción completa

Detalles Bibliográficos
Autores principales: Santini, Daniele, Citarella, Fabrizio, Vincenzi, Bruno, Russano, Marco, Tonini, Giuseppe, Stellato, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737677/
https://www.ncbi.nlm.nih.gov/pubmed/31528502
http://dx.doi.org/10.1186/s40164-019-0146-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737677/
https://www.ncbi.nlm.nih.gov/pubmed/31528502
http://dx.doi.org/10.1186/s40164-019-0146-9

Ejemplares similares